Provider review
Eden Tirzepatide Review
Eden is reviewed here against a fixed evidence checklist: legal identity, program type, advertised and effective tirzepatide pricing, mandatory fees, dose coverage, pharmacy verification, clinician model, and cancellation terms. Its captured tirzepatide pricing normalises to about $298 per month (effective recurring cost: medication plus every mandatory fee, computed from the captured components). Pharmacy, clinician, and policy fields remain unverified and are shown as pending.
Key takeaways
- Normalised tirzepatide cost is about $298 per month on the basis of effective recurring cost: medication plus every mandatory fee, computed from the captured components.
- Mandatory fees recorded: Membership separate.
- Compounding pharmacy, licence, facility type, clinicians, states, and cancellation terms are all unverified and shown as Verification Pending rather than inferred.
- This publication has no financial, affiliate, referral, or sponsorship relationship with this provider.
- Compounded tirzepatide is not FDA approved and is not reviewed by the FDA before sale.
| Provider | Eden |
|---|---|
| Operating status | Active |
| Program type | Compounded-GLP-1-focused |
| Tirzepatide price (as captured) | Medication $199/month; membership $39 first month then $99/month, producing about $298/month ongoing |
| Normalised monthly cost | $298 (effective recurring cost: medication plus every mandatory fee, computed from the captured components) |
| Mandatory fees | Membership separate |
| Medication included | Medication component separate from membership |
| Billing cadence | Monthly |
| Compounding pharmacy | Verification Pending |
| Pharmacy licence | Verification Pending |
| Facility type (503A/503B) | Verification Pending |
| Named clinicians | Verification Pending |
| States served | Verification Pending |
| Dose coverage | Verification Pending |
| Shipping terms | Verification Pending |
| Cancellation policy | Verification Pending |
| Refund policy | Verification Pending |
| Auto-renewal terms | Verification Pending |
| Publisher relationship | None — no financial, ownership, affiliate, referral, or sponsorship relationship |
| Evidence source | Official provider |
| Source confidence | High |
| Price verified | 2026-07-20 |
What is the verdict on this provider?
Eden discloses enough detail to compute an effective recurring cost of about $298 per month including mandatory fees. That transparency is the reason it can be ranked like-for-like; whether the figure is competitive is a separate question answered in the cost analysis below.
What does tirzepatide actually cost at Eden?
The captured source states: Medication $199/month; membership $39 first month then $99/month, producing about $298/month ongoing. Normalised, that is about $298 per month on the basis of effective recurring cost: medication plus every mandatory fee, computed from the captured components. Mandatory fees recorded: Membership separate.
The figure that matters for a treatment that continues for years is the recurring cost after any introductory period, including every mandatory fee. Advertised headline prices frequently exclude membership, consultation, or shipping charges, which is why this site normalises before comparing.
What does the captured source actually state?
| Field | Text as captured from the provider's own page |
|---|---|
| Tirzepatide pricing, as published | Medication $199/month; membership $39 first month then $99/month, producing about $298/month ongoing |
| Semaglutide pricing, as published | Medication $99/month; membership $39 first month then $99/month, producing about $198/month ongoing |
| Fee structure, as published | Membership separate |
| Medication inclusion, as published | Medication component separate from membership |
| Billing cadence, as published | Monthly |
| Evidence type | Current advertised component pricing |
| Capture caveat | Effective total is calculated from advertised recurring membership plus medication. |
How should the Eden pricing structure be read?
Eden publishes a monthly billing cadence in the captured source. Month-to-month billing generally costs more per month than a committed tier but leaves less money at risk if treatment is stopped early, which matters most before tolerance is established.
The same source also publishes semaglutide pricing, which is useful context: a provider pricing both drugs allows a switch without changing provider, though the two are not interchangeable and any change is a prescriber decision.
Source confidence is recorded as high because the figures come from Official provider rather than secondary reporting. That describes the capture, not how long it will remain accurate — pricing in this market changes frequently.
What has not been verified?
What should you confirm before enrolling?
- The recurring price after any introductory or first-month rate, in writing.
- Every mandatory fee: membership, consultation, shipping, and any dose-related surcharge.
- Which compounding pharmacy dispenses, its state licence number, and whether it is 503A or 503B.
- What happens to the price when your dose increases.
- The cancellation method, notice period, and whether prepaid months are refundable.
- Whether the plan auto-renews and how to stop it.
- That a licensed clinician reviews your intake and is reachable for side-effect questions.
What are the alternatives?
Primary source: Eden pricing page · captured 2026-07-20. Effective total is calculated from advertised recurring membership plus medication.
What does this provider cost over two years?
| Group | $/month |
|---|---|
| Committed tier | 298 |
| Month-to-month | 298 |
| Series | Start | 6 mo | 12 mo | 18 mo | 24 mo |
|---|---|---|---|---|---|
| Committed tier | 0$ | 1788.0$ | 3576.0$ | 5364.0$ | 7152.0$ |
| Month-to-month | 0$ | 1788.0$ | 3576.0$ | 5364.0$ | 7152.0$ |
What is Eden's status after the compounding change?
Eden was captured on 2026-07-20 advertising compounded tirzepatide. That capture predates nothing — it is recent — but the legal basis for the product it describes changed before it was taken. Compounding of tirzepatide was permitted only while the drug sat on the FDA shortage list. The shortage was declared resolved on 2 October 2024 and reaffirmed by declaratory order on 19 December 2024, and enforcement discretion ended on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities.
This site therefore treats Eden's captured pricing as a dated historic record of what the compounded market charged, not as a live offer to compare against others. If Eden continues to advertise compounded tirzepatide, the useful question is not whether the price is competitive but what legal basis the product is supplied under and which state-licensed pharmacy dispenses it. Neither is verified in this record.
| Question | Position for Eden | How this site treats it |
|---|---|---|
| Was compounded tirzepatide advertised at capture? | Yes | Recorded as a dated historic figure |
| Operating status at capture | Active | Reported as captured; not re-verified since |
| Legal basis for continued compounded supply | Not disclosed in the captured source | Verification Pending — not inferred |
| Dispensing pharmacy identity | Not disclosed | Verification Pending |
| Whether approved products are now offered | Not established in this record | Verification Pending — ask the provider directly |
How was Eden's pricing classified?
Every provider on this site passes through the same four-part price test before it can appear in a cost ranking. The test asks whether the captured source states a recurring price, whether medication is included in that price, whether every mandatory fee is identified, and whether the figure describes the standard subcutaneous injection rather than an alternative formulation. Eden is assessed below against each part in turn.
| Test | Result for this provider | Why it matters |
|---|---|---|
| A recurring price is stated | Yes | Medication $199/month; membership $39 first month then $99/month, producing about $298/month ongoing |
| Medication is included in that price | Medication component separate from membership | Determines whether the figure is the whole cost or only part of it |
| Every mandatory fee is identified | Membership separate | A separate recurring membership or care fee changes the real monthly outlay |
| The figure describes the standard injection | standard injection | Microdose, ODT, sublingual and troche preparations are not comparable with an injection |
| Classification result | verified all in | effective recurring cost: medication plus every mandatory fee, computed from the captured components |
Eden passes. The captured source states a recurring figure of $298 per month that includes medication and carries no separate mandatory membership charge, which is what makes it comparable with other providers on the same basis. That is less common in this market than it sounds: most captured sources advertise a starting price whose fee structure is left unstated, and those records cannot be placed on the same axis.
What would Eden cost over time?
Because SURMOUNT-4 showed that stopping tirzepatide produces substantial weight regain, the financially relevant question is not what the first month costs but what sustained treatment costs. The table below projects Eden's verified recurring rate across the horizons that maintenance actually implies. It assumes the price and the dose remain unchanged, neither of which is guaranteed — dose-coverage terms are unverified for this provider.
| Horizon | Months | Committed rate | Month-to-month | Difference |
|---|---|---|---|---|
| First quarter | 3 | $894 | $894 | — |
| Six months | 6 | $1,788 | $1,788 | — |
| One year | 12 | $3,576 | $3,576 | — |
| Two years | 24 | $7,152 | $7,152 | — |
| Three years | 36 | $10,728 | $10,728 | — |
How does Eden compare with the providers that can be ranked?
Eden sits at position 5 of 5 among providers whose all-in recurring cost is verifiable. The lowest verified rate in the dataset is TRYM Health at $125 per month; the highest is Eden at $298. Eden is $173 per month above the lowest, which compounds to $2,076 over a year and $4,152 over two.
| Provider | Verified all-in monthly | Basis of the figure |
|---|---|---|
| TRYM Health | $125 | complete published commitment ladder for the standard injection: medication included, no separate membership o |
| NexLife | $186 | complete published commitment ladder for the standard injection: medication included, no separate membership o |
| Fridays | $240 | advertised monthly rate with medication included and no separate membership fee |
| Mochi Health | $278 | effective recurring cost: medication plus every mandatory fee, computed from the captured components |
| Eden | $298 | effective recurring cost: medication plus every mandatory fee, computed from the captured components |
What else does Eden's captured record contain?
The full record held for Eden is reproduced below. This site publishes the underlying capture rather than only its own summary, so a reader can see exactly what the interpretation rests on and disagree with it if the reading looks wrong.
| Field | Value held for this provider |
|---|---|
| Programme category | Compounded-GLP-1-focused |
| Operating status | Active |
| Tirzepatide pricing, as captured | Medication $199/month; membership $39 first month then $99/month, producing about $298/month ongoing |
| Semaglutide pricing, as captured | Medication $99/month; membership $39 first month then $99/month, producing about $198/month ongoing |
| Mandatory fees, as captured | Membership separate |
| Medication inclusion | Medication component separate from membership |
| Billing cadence | Monthly |
| Evidence type | Current advertised component pricing |
| Capture caveats | Effective total is calculated from advertised recurring membership plus medication. |
| Source | Official provider |
| Source confidence | High |
| Price verified | 2026-07-20 |
Eden's semaglutide pricing is recorded because the relationship between a provider's semaglutide and tirzepatide pricing is informative on its own. Semaglutide is typically the cheaper of the two in this market, and a provider whose tirzepatide premium is unusually large or unusually small relative to its semaglutide rate is worth asking about — it can reflect different pharmacy sourcing, different dose coverage, or a promotional structure that will not persist. For Eden the captured semaglutide text reads: Medication $99/month; membership $39 first month then $99/month, producing about $198/month ongoing
The capture for Eden is rated high confidence, meaning the figures were stated plainly on a first-party page in a form that left little room for interpretation. High confidence concerns the accuracy of the transcription, not the durability of the price: providers in this market change pricing frequently, and the verification date above is the honest boundary on how much weight the figure should carry.
What should you ask Eden before enrolling?
These questions are selected against the specific gaps in Eden's record rather than being a generic checklist. Ask them in writing and keep the reply: a verbal assurance from a sales channel is not a contractual term, and terms are what govern a dispute.
- What is the recurring monthly price after any introductory or first-month rate?
- Is the medication itself included in that price, or billed separately?
- What recurring fees apply on top of the medication, and are any of them waived initially?
- Which compounding pharmacy prepares the medication, and what is its state licence number?
- Is that pharmacy a 503A compounder or a 503B outsourcing facility?
- Does the price change when the dose increases to 10 mg or 15 mg?
- What concentration is dispensed, in mg/mL, and what beyond-use date is assigned?
- How is the plan cancelled, what notice is required, and are prepaid months refundable?
- Does the plan auto-renew, and how is renewal stopped?
- Which licensed clinician reviews the intake, and how are side-effect questions handled?
A provider that answers all of these in writing has demonstrated something meaningful about how it operates. A provider that will not name its compounding pharmacy before payment has also told you something, and it is worth weighing that refusal as evidence in its own right.
What would moving from Eden to an approved product cost?
Eden's captured recurring figure was $298 per month. Zepbound self-pay through the manufacturer's direct channel is $299 per month at the starting dose and $449 at maintenance doses of 7.5 mg and above. Moving from this provider's captured rate to the approved product would therefore represent an increase of about $1 per month at the starting dose and $151 per month at maintenance — roughly $1,812 over a year.
| Group | $/month |
|---|---|
| Eden (captured, historic) | 298 |
| Zepbound self-pay, 2.5 mg | 299 |
| Zepbound self-pay, 7.5 mg+ | 449 |
| Zepbound retail, no coverage | 1086 |
That increase is the honest cost of the regulatory change, and it is why an insurance route matters more now than provider comparison did before. A commercially insured reader with a covered weight-management benefit may pay a small copay rather than either figure above, which makes a coverage appeal the highest-value action available to most people in this position.
What should you ask Eden now?
These questions are written for the post-shortage position rather than for a price comparison. The first three matter most: a provider still advertising compounded tirzepatide should be able to explain its legal basis and name its pharmacy, and an inability to do either is the most informative answer available.
- Is Eden still supplying tirzepatide, and if so in what form?
- If a compounded product is still offered, what is the legal basis for supplying it?
- Which state-licensed pharmacy dispenses, and what is its licence number?
- Is the pharmacy a 503A compounder or a 503B outsourcing facility?
- Does the programme now offer FDA-approved Zepbound or Mounjaro instead?
- If an approved product is offered, is the price the medication alone or medication plus programme fees?
- Will the programme support an insurance prior-authorisation or appeal on your behalf?
- What happens to any prepaid balance if the programme can no longer supply what you paid for?
- How is cancellation handled, what notice is required, and are unused months refunded?
- Which licensed clinician is responsible for your care, and how are they contacted?
Prepaid balances deserve particular attention. Anyone who prepaid a multi-month compounded programme before the enforcement deadlines has a reasonable question about what they were supplied afterwards, and that question is worth putting in writing.
What do the technical terms on this page mean?
Definitions for the 10 technical terms this page uses, including 503A, 503B, GLP-1, auto-renewal — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
| auto-renewal | A term under which a plan renews automatically unless cancelled. Combined with a notice period, it determines how much money is at risk if treatment stops. |
| beyond-use date | The date after which a compounded preparation should not be used. It is assigned by the compounding pharmacy based on its own conditions, and is typically much shorter than a manufacturer expiry date derived from formal stability testing. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| effective monthly cost | The recurring amount actually paid each month once every mandatory fee is included. It is frequently higher than the advertised medication price, which is why this site normalises before ranking. |
| membership fee | A recurring charge separate from the medication price, common in telehealth weight programmes. It can add $40 to $80 per month and frequently reverses which provider is genuinely cheaper. |
| mg/mL | Milligrams of drug per millilitre of liquid — the concentration. Two vials containing the same nominal dose can require different injection volumes if their concentrations differ, which is why this site does not publish volume calculations. |
| subcutaneous | Beneath the skin. Tirzepatide is given by subcutaneous injection, usually into the abdomen, thigh, or upper arm. |
Frequently asked questions
How much does tirzepatide cost at Eden?
The captured source normalises to about $298 per month (effective recurring cost: medication plus every mandatory fee, computed from the captured components). Confirm the recurring price and all mandatory fees before enrolling.
Which pharmacy does Eden use?
Not verified. The compounding pharmacy identity, its state licence, and whether it is a 503A or 503B facility have not been confirmed first-party, so nothing is asserted.
Is Eden cheaper than other providers?
Only providers whose all-in effective monthly cost can be computed are ranked against each other. See the most affordable page for the eligible set and the excluded records with reasons.
Does Tirzepatide Editorial earn a commission from Eden?
No. There is no financial, ownership, affiliate, referral, or sponsorship relationship with this or any provider. Outbound links are nofollow and carry only our own analytics parameters.
Is compounded tirzepatide FDA approved?
No. Compounded tirzepatide is not FDA approved and is not reviewed by the FDA for safety, effectiveness, or quality before sale.
Sources for this page
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.